By Phil Boeyen, ShareChat Business News Editor
Thursday 22nd February 2001 |
Text too small? |
For the six months ended December Ebos profit rose just 5% on the previous year to $1.956 million, despite sales increasing to $50.4 million from $34 million in 1999.
"The overall result is best described as credible in a climate presently unfavourable to importers," the company said in a statement.
Ebos says margin impact of ongoing weakness in New Zealand and Australian currencies continues to be the greatest influence on profitability and has neutralised the very positive impact of the group's growth initiatives.
Although New Zealand operating divisions and the Richard Thomson subsidiary in Australia reached profit targets, the company's Australian orthopaedic subsidiary returned only a breakeven performance compared with a profit the previous half year.
Ebos says its directors and senior executives continue to work on a range of growth opportunities, particularly those that add brand security or add value to existing business units.
The company is planning a 6.5 cents per share dividend, fully imputed.
No comments yet
Ebos still hungry for acquisitions after $1.1 bln Symbion deal, Waller says
Ebos meets prospectus forecast with 5.5 percent gain in FY profit
Ebos shareholders approve $1.1 billion purchase of Symbion
Ebos grabs scale with $1.1 bln purchase of Aussie pharma distributor Symbion
Ebos kicks tyres on potential acquisitions
Ebos lifts profit by 19%, targets growth in animal health
Ebos funding line smaller than previously flagged at $135 mln
Ebos Group
Ebos backs off British purchase, evaluates "significant" Australasian asset
Ebos reports higher profit, looks for acquisitions